Immunosuppression and Surgery‐Free Interval in Granulomatosis With Polyangiitis Airway Stenosis
The Laryngoscope · 2026
DOI: 10.1002/lary.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Sydney J Torres und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Granulomatosis with Polyangiitis, Rituximab, Tracheal Stenosis, Laryngostenosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Subglottic and tracheal stenosis (SGS, TS) are severe manifestations of granulomatosis with polyangiitis (GPA), often‐requiring endoscopic airway intervention and systemic immunosuppression. Rituximab (RTX) has shown efficacy for systemic GPA, but its role in SGS and TS remains unclear, with reports of both benefit and relapse. This study evaluated the impact of RTX and cyclophosphamide (CTX) on surgery‐free intervals (SFIs) in GPA‐associated SGS and TS.
Methods
A retrospective chart review was conducted on GPA patients with SGS or TS treated at a tertiary center between 1992 and 2023. Therapeutic RTX exposure was defined as 3–9 months post‐induction or within 1 year of maintenance, and CTX during regular dosing before transitioning to another maintenance regimen. SFIs, calculated as time between endoscopic interventions, were compared with and without RTX and CTX exposure using weighted t ‐tests.
Results
A total of 55 patients met inclusion; 44 (80%) underwent at least one endoscopic intervention and 34 of those patients (77%) received RTX and/or CTX. Median follow‐up time was 10.2 years (range 0.8–29.5 years). Mean SFIs were significantly longer during therapeutic RTX exposure or remission (45 ± 8 months) versus non‐therapeutic intervals (20 ± 6 months) ( p = 0.046). Prior RTX or CTX use, though not definitionally therapeutic, significantly increased mean SFI from 22 to 25 months compared to no exposure ( p = 0.029). CTX alone did not significantly increase SFI.
Conclusion
Rituximab may contribute to longer intervals between endoscopic airway intervention and delay relapse in GPA‐related airway stenosis, supporting its role in stabilization of airway manifestations. Multidisciplinary management remains essential for this life‐threatening GPA manifestation. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Michigan Medical School, Ann Arbor, Michigan, USA.
- University of Michigan Department of Otolaryngology-Head and Neck Surgery, Ann Arbor, Michigan, USA.
- Division of Rheumatology, University of Michigan Department of Internal Medicine, Ann Arbor, Michigan, USA.
- MidMichigan Ear, Nose, and Throat East Lansing, East Lansing, Michigan, USA.
ORCID-Profile: Sydney J Torres, Norman D Hogikyan, Robert J Morrison
Zitieren
APA
Torres, S. J., Neevel, A. J., Ford, J. A., Kashat, L., Hogikyan, N. D., Kupfer, R. A., & Morrison, R. J. (2026). Immunosuppression and Surgery‐Free Interval in Granulomatosis With Polyangiitis Airway Stenosis. The Laryngoscope. https://doi.org/10.1002/lary.70249
Vancouver
Torres SJ, Neevel AJ, Ford JA, Kashat L, Hogikyan ND, Kupfer RA, et al. Immunosuppression and Surgery‐Free Interval in Granulomatosis With Polyangiitis Airway Stenosis. The Laryngoscope. 2026. doi:10.1002/lary.70249
BibTeX
@article{Torres2026,
author = {Torres, Sydney J and Neevel, Andrew J and Ford, Julia A and Kashat, Lawrence and Hogikyan, Norman D and Kupfer, Robbi A and Morrison, Robert J},
title = {Immunosuppression and Surgery‐Free Interval in Granulomatosis With Polyangiitis Airway Stenosis},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70249}
}
EUVIMED